FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385477209> ?p ?o ?g. }

• W4385477209 endingPage "6350" @default.
• W4385477209 startingPage "6339" @default.
• W4385477209 abstract "Lymphomas are not infrequently associated with the Epstein-Barr virus (EBV), and EBV positivity is linked to worse outcomes in several subtypes. Nanatinostat is a class-I selective oral histone deacetylase inhibitor that induces the expression of lytic EBV BGLF4 protein kinase in EBV+ tumor cells, activating ganciclovir via phosphorylation, resulting in tumor cell apoptosis. This phase 1b/2 study investigated the combination of nanatinostat with valganciclovir in patients aged ≥18 years with EBV+ lymphomas relapsed/refractory to ≥1 prior systemic therapy with no viable curative treatment options. In the phase 1b part, 25 patients were enrolled into 5 dose escalation cohorts to determine the recommended phase 2 dose (RP2D) for phase 2 expansion. Phase 2 patients (n = 30) received RP2D (nanatinostat 20 mg daily, 4 days per week with valganciclovir 900 mg orally daily) for 28-day cycles. The primary end points were safety, RP2D determination (phase 1b), and overall response rate (ORR; phase 2). Overall, 55 patients were enrolled (B-non-Hodgkin lymphoma [B-NHL], [n = 10]; angioimmunoblastic T-cell lymphoma-NHL, [n = 21]; classical Hodgkin lymphoma, [n = 11]; and immunodeficiency-associated lymphoproliferative disorders, [n = 13]). The ORR was 40% in 43 evaluable patients (complete response rate [CRR], 19% [n = 8]) with a median duration of response of 10.4 months. For angioimmunoblastic T-cell lymphoma-NHL (n = 15; all refractory to the last prior therapy), the ORR/CRR ratio was 60%/27%. The most common adverse events were nausea (38% any grade) and cytopenia (grade 3/4 neutropenia [29%], thrombocytopenia [20%], and anemia [20%]). This novel oral regimen provided encouraging efficacy across several EBV+ lymphoma subtypes and warrants further evaluation; a confirmatory phase 2 study (NCT05011058) is underway. This phase 1b/2 study is registered at www.clinicaltrials.gov as #NCT03397706." @default.
• W4385477209 created "2023-08-03" @default.
• W4385477209 creator A5000482632 @default.
• W4385477209 creator A5001663845 @default.
• W4385477209 creator A5003367392 @default.
• W4385477209 creator A5003883532 @default.
• W4385477209 creator A5004461149 @default.
• W4385477209 creator A5012846289 @default.
• W4385477209 creator A5013717203 @default.
• W4385477209 creator A5014919457 @default.
• W4385477209 creator A5026597677 @default.
• W4385477209 creator A5032591000 @default.
• W4385477209 creator A5036282225 @default.
• W4385477209 creator A5039680248 @default.
• W4385477209 creator A5040695566 @default.
• W4385477209 creator A5041950455 @default.
• W4385477209 creator A5049232328 @default.
• W4385477209 creator A5054343933 @default.
• W4385477209 creator A5068831487 @default.
• W4385477209 creator A5080043320 @default.
• W4385477209 creator A5083735394 @default.
• W4385477209 creator A5090964554 @default.
• W4385477209 date "2023-10-24" @default.
• W4385477209 modified "2023-10-18" @default.
• W4385477209 title "Targeted therapy with nanatinostat and valganciclovir in recurrent Epstein-Barr virus-positive lymphoid malignancies: a Phase 1b/2 study" @default.
• W4385477209 cites W1038865554 @default.
• W4385477209 cites W1491144410 @default.
• W4385477209 cites W1593352795 @default.
• W4385477209 cites W1804466049 @default.
• W4385477209 cites W1849032606 @default.
• W4385477209 cites W1984710154 @default.
• W4385477209 cites W1985199344 @default.
• W4385477209 cites W1997131488 @default.
• W4385477209 cites W2010358693 @default.
• W4385477209 cites W2017517248 @default.
• W4385477209 cites W2039745983 @default.
• W4385477209 cites W2053361200 @default.
• W4385477209 cites W2068970201 @default.
• W4385477209 cites W2096520038 @default.
• W4385477209 cites W2099077578 @default.
• W4385477209 cites W2099129819 @default.
• W4385477209 cites W2102015088 @default.
• W4385477209 cites W2116068882 @default.
• W4385477209 cites W2117074511 @default.
• W4385477209 cites W2119147717 @default.
• W4385477209 cites W2125514026 @default.
• W4385477209 cites W2129738847 @default.
• W4385477209 cites W2130049805 @default.
• W4385477209 cites W2130121731 @default.
• W4385477209 cites W2151876257 @default.
• W4385477209 cites W2153747221 @default.
• W4385477209 cites W2154255170 @default.
• W4385477209 cites W2165012318 @default.
• W4385477209 cites W2247938225 @default.
• W4385477209 cites W2253645956 @default.
• W4385477209 cites W2310716991 @default.
• W4385477209 cites W2324553589 @default.
• W4385477209 cites W2414742524 @default.
• W4385477209 cites W2480418585 @default.
• W4385477209 cites W2484616545 @default.
• W4385477209 cites W2526219494 @default.
• W4385477209 cites W2560808900 @default.
• W4385477209 cites W2589352673 @default.
• W4385477209 cites W2610090714 @default.
• W4385477209 cites W2755325205 @default.
• W4385477209 cites W2796416879 @default.
• W4385477209 cites W2796967993 @default.
• W4385477209 cites W2809654973 @default.
• W4385477209 cites W2910417015 @default.
• W4385477209 cites W2952387914 @default.
• W4385477209 cites W2953208154 @default.
• W4385477209 cites W2963804040 @default.
• W4385477209 cites W2979799584 @default.
• W4385477209 cites W3083712668 @default.
• W4385477209 cites W3109685499 @default.
• W4385477209 cites W3132786489 @default.
• W4385477209 cites W3155878711 @default.
• W4385477209 cites W3162317822 @default.
• W4385477209 cites W3193891730 @default.
• W4385477209 cites W3208965455 @default.
• W4385477209 cites W3211777932 @default.
• W4385477209 cites W3213689858 @default.
• W4385477209 cites W4205708862 @default.
• W4385477209 cites W4214810944 @default.
• W4385477209 cites W4281625438 @default.
• W4385477209 cites W4295921243 @default.
• W4385477209 cites W4310121368 @default.
• W4385477209 doi "https://doi.org/10.1182/bloodadvances.2023010330" @default.
• W4385477209 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37530631" @default.
• W4385477209 hasPublicationYear "2023" @default.
• W4385477209 type Work @default.
• W4385477209 citedByCount "0" @default.
• W4385477209 crossrefType "journal-article" @default.
• W4385477209 hasAuthorship W4385477209A5000482632 @default.
• W4385477209 hasAuthorship W4385477209A5001663845 @default.
• W4385477209 hasAuthorship W4385477209A5003367392 @default.
• W4385477209 hasAuthorship W4385477209A5003883532 @default.
• W4385477209 hasAuthorship W4385477209A5004461149 @default.

• next